哮喘治疗药物生物通路的基因多态性研究进展

郭丹丹; 郑湘榕

doi:10.7499/j.issn.1008-8830.2016.06.019

PDF(1590 KB)

HTML

中国当代儿科杂志 ›› 2016, Vol. 18 ›› Issue (6) : 567-573. DOI: 10.7499/j.issn.1008-8830.2016.06.019

综述

哮喘治疗药物生物通路的基因多态性研究进展

郭丹丹, 郑湘榕

作者信息 +

Research advances in gene polymorphisms in biological pathways of drugs for asthma

GUO Dan-Dan, ZHENG Xiang-Rong

Author information +

文章历史 +

摘要

哮喘治疗药物生物通路的基因多态性研究是指运用遗传药理学的方法,如全基因组关联研究(GWAS)、候选基因研究(CGS)、基因组测序、混合作图分析、连锁不平衡等来发现、确定并重复认证哮喘患者某一个或多个基因多态性位点(SNPs)联合影响药物疗效的研究,以期为哮喘患者提供效益最大、副作用最低、花费最少的医疗策略,从而实现个体化医疗。哮喘的主要治疗药物包括β2受体激动剂、糖皮质激素、白三烯调节剂及其他等,该文就这些哮喘常用药物的生物通路多态性位点分析研究成果做一综述,以期对未来的哮喘遗传药理研究提供一定的指导,使得哮喘的个体化医疗能够更快实现。

Abstract

The studies on gene polymorphisms in biological pathways of the drugs for the treatment of asthma refer to the studies in which pharmacogenetic methods, such as genome-wide association studies, candidate gene studies, genome sequencing, admixture mapping analysis, and linkage disequilibrium, are used to identify, determine, and repeatedly validate the effect of one or more single nucleotide polymorphisms on the efficacy of drugs. This can provide therapeutic strategies with optimal benefits, least side effects, and lowest costs to patients with asthma, and thus realize individualized medicine. The common drugs for asthma are β2 receptor agonists, glucocorticoids, and leukotriene modifiers. This article reviews the research achievements in polymorphisms in biological pathways of the common drugs for asthma, hoping to provide guidance for pharmacogenetic studies on asthma in future and realize individualized medicine for patients with asthma soon.

导出引用

郭丹丹, 郑湘榕. 哮喘治疗药物生物通路的基因多态性研究进展[J]. 中国当代儿科杂志. 2016, 18(6): 567-573 https://doi.org/10.7499/j.issn.1008-8830.2016.06.019

GUO Dan-Dan, ZHENG Xiang-Rong. Research advances in gene polymorphisms in biological pathways of drugs for asthma[J]. Chinese Journal of Contemporary Pediatrics. 2016, 18(6): 567-573 https://doi.org/10.7499/j.issn.1008-8830.2016.06.019

参考文献

[1] Duan QL, Tantisira KG. Pharmacogenetics of asthma therapy[J]. Current Pharm Des, 2009, 15(32): 3742-3753.
[2] 洪建国, 曲政海, 谢宁. 序言及总论[M]//曲政海, 林荣军, 孙向红. 儿童支气管哮喘. 北京: 人民军医出版社, 2014: 1-12.
[3] 孙金霞, 崔玉宝. 哮喘的遗传学研究进展[J]. 医学综述, 2014, 20(01): 3-7.
[4] Hizawa N. Pharmacogenetics of beta 2-agonists[J]. Allergol Int, 2011, 60(3): 239-246.
[5] Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment[J]. BMJ, 1993, 306(6884): 1034-1037.
[6] Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol[J]. Chest, 2006, 129(1): 15-26.
[7] Shahane G, Parsania C, Sengupta D, et al. Molecular insights into the dynamics of pharmacogenetically important N-terminal variants of the human β2-adrenergic receptor[J]. PLoS Comput Biol, 2014, 10(12): e1004006.
[8] Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma[J]. Respir Crit Care Med, 2005, 171(6): 563-570.
[9] Bandaru S, Akka J, Marri VK, et al. Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics[J]. Inflammation, 2015, 38(6): 2146-2155.
[10] Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratifid, randomised, placebocontrolled cross-over trial[J]. Lancet, 2004, 364(9444): 1505-1512.
[11] Shah NJ, Vinod Kumar S, Gurusamy U, et al. Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma[J]. J Asthma, 2015, 52(8): 755-762.
[12] Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without flticasone propionate[J]. Respir Crit Care Med, 2010, 181(7): 676-687.
[13] Bandaru S, Akka J, Marri VK, et al. Analysis of ADRB2 (Arg16Gly) Gene Variant with Susceptibility, Pharmacogenetic Response and Disease Severity in South Indian Asthmatics[J].Inflamation, 2015, 38(6): 2146-2155.
[14] Fu WP, Zhao ZH, Zhong L, et al. Relationship between polymorphisms in the 5' leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene and asthma in a Han population from southwest China[J]. Respirology, 2011, 16(8): 1221-1227.
[15] Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to long-acting beta2 agonist in asthma (LARGE trial): a genotypestratified, randomised, placebo-controlled, crossover trial[J]. Lancet, 2009(374): 1754-1764.
[16] Wechsler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs long-acting β-agonist in combination with inhaled corticosteroids in black adults with asthma: The BELT randomized clinical trial[J]. JAMA, 2015, 314(16): 1720-1730.
[17] Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies[J].Lancet, 2007, 370(9605): 2118-2125.
[18] Ortega VE, Meyers DA, Bleecker ER. Asthma pharmacogenetics and the development of genetic profies for personalized medicine[J]. Pharmacogenomics Pers Med, 2015, 8: 9-22.
[19] Green SA, Cole G, Jacinto M, et al. A polymorphism of the human beta 2- adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor[J]. Biol Chem, 1993, 268(31): 23116-23121.
[20] Green SA, Rathz DA, Schuster AJ, et al. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s)[J]. Pharmacol, 2001, 421(3): 141-147.
[21] Thomsen M, Nordestgaard BG, Sethi AA, et al. Beta2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies[J]. Eur Respir J, 2012, 39(3): 558-566.
[22] Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare genetic variants inADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population[J]. Lancet Respir Med, 2014, 2(3): 204-213.
[23] Poon AH, Tantisira KG, Litonjua AA, et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma[J]. Pharmacogenet Genomics, 2008, 18(5): 373-382.
[24] Drake KA, Torgerson DG, Gignoux CR, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants[J]. Allergy Clin Immunol, 2014, 133(2): 370-378.
[25] Litonjua AA, Lasky-Su J, Schneiter K, et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts[J]. Respir Crit Care Med, 2008, 178(7): 688-694.
[26] Sy HY, Ko FWS, Chu HY, et al. Asthma and bronchodilator responsiveness are associated with polymorphic markers of ARG1, CRHR2 and chromosome 17q21[J]. Pharmacogenet Genomics, 2012, 22(7): 517-524.
[27] Vonk JM, Postma DS, Maarsingh H, et al. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response[J]. Pharmacogenet Genomics, 2010, 20(3): 179-186.
[28] Duan QL, Gaume BR, Hawkins GA, et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response[J]. Respir Crit Care Med, 2011, 183(4): 449-454.
[29] Iordanidou M, Paraskakis E, Tavridou A, et al. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting beta2-agonists in asthmatic children[J]. Pharmacogenomics, 2012, 13(12): 1363-1372.
[30] Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus[J].Am J Respir Crit Care Med, 2012, 185(12): 1286-1291.
[31] Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids[J]. Hum Mol Genet, 2004, 13(13): 1353-1359.
[32] Hawkins GA, Lazarus R, Smith RS, et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids[J]. Allergy Clin Immunol, 2009, 123(6): 1376-1383.
[33] Tantisira KG, Small KM, Litonjua AA, et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma:interaction between beta-agonist and corticosteroid pathways[J]. Hum Mol Genet, 2005, 14(12): 1671-1677.
[34] Kim SH, Ye YM, Lee HY, et al. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy[J]. J Clin Pharm Ther, 2011, 36(3): 399-405.
[35] Ye YM, Lee HY, Kim SH, et al. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment[J]. J Clin Pharm Ther, 2009, 34(6): 693-701.
[36] Lopert A, Rijavec M, Zavbi M, et al. Asthma treatment outcome in adults is associated with rs9910408 in TBX21 gene[J]. Sci Rep, 2013, 3: 2915.
[37] Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma[J]. N Engl J Med, 2011, 365(13): 1173-1183.
[38] Berce V, Kozmus CE, Potočnik U. Association among ORMDL3 gene expression,17q21 polymorphism and response to treatment with inhaled corticosteroids in children with asthma[J]. Pharmacogenomics, 2013, 13(6): 523-529.
[39] Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control[J]. J Pediatr, 2013, 162(6): 1222-1227.
[40] Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment[J]. Nat Genet, 1999, 22(2): 168-170.
[41] Lima JJ, Zhang S, Grant A, et al. Inflence of leukotriene pathway polymorphisms on response to montelukast in asthma[J]. Am J Respir Crit Care Med, 2006, 173(4): 379-385.
[42] Kotani H, Kishi R, Mouri A, et al. Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma[J]. J Clin Parm Ther, 2012, 37(1): 112-116.
[43] 蔡畅,周美茜, 李玉苹, 等. 支气管哮喘患者白三烯基因多态性与抗白三烯治疗的相关性研究[J]. 中华结核和呼吸杂志, 2011, 34(5): 362-366.
[44] Nwokoro C, Pandya H, Turner S, et al. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial[J]. Efficacy Mech Eval, 2015, 2(6): 1-10.
[45] Mougey E, Lang JE, Allayee H, et al. ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma[J]. Clin Exp Allergy, 2013, 43(5): 512-520.
[46] Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response[J]. Pharmacogenet Genomics, 2009, 19(2): 129-138.
[47] Kim KA, Lee HM, Joo HJ, et al. Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans[J]. J Clin Pharmacol, 2013, 53(11): 1186-1193.
[48] Tapaninen T, Karonen T, Backman JT, et al. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren[J].Pharmacogenet Genomics, 2013, 23(1): 19-24.
[49] Dahlin A, Litonjua A, Lima JJ, et al. Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PLoS One, 2015, 10(6): e0129385.
[50] Dahlin A, Litonjua A, Irvin CG, et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J, 2016, 16(2): 151-157.